

## SEARCH REQUEST FORM

Scientific and Technical Information Center

187  
 Requester's Full Name: SUDHAKER PATEL Examiner #: 77018 Date: 8/16/00  
 Art Unit: 1624 Phone Number 308 4709 Serial Number: 09529098  
 Mail Box and Bldg/Room Location: CM14E18 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*  
 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched:  
 Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or  
 utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if  
 known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: AMIDE DERIVATIVES OR SALTS THEREOF

Inventors (please provide full names): TATSUYA MARUYAMA et al.

Earliest Priority Filing Date: ASAP → Mr. J. Dingmann or Mr. B. O'Brien or Mrs. S. Hertenstein please

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

COMPOUNDS: claims: 1-6

COMPOSITION: claim: 7


Method/USE: PHARMACEUTICAL: claim 8

COMPOUNDS OF INTEREST PL also

Structure

Table 4

No.	X	B	No.	X	B	No.	X	B
1			2			3		
4			5			6		



No.	R <sup>2a</sup>	X	B	No.	R <sup>2a</sup>	X	B
13	H			14	H		

## STAFF USE ONLY

Searcher: \_\_\_\_\_

Date Searcher Picked Up: \_\_\_\_\_

Date Completed: 8-21-00

Searcher Prep & Review Time: 20

Clerical Prep Time: \_\_\_\_\_

Online Time: 13

## Type of Search

NA Sequence (#) \_\_\_\_\_ STN 104

AA Sequence (#) \_\_\_\_\_ Dialog \_\_\_\_\_

Bibliographic \_\_\_\_\_ Dr. Link \_\_\_\_\_

Litigation \_\_\_\_\_ Lexis/Nexis \_\_\_\_\_

Fulltext \_\_\_\_\_ Sequence Systems \_\_\_\_\_

Patent Family \_\_\_\_\_ WWW/Internet \_\_\_\_\_


Other \_\_\_\_\_ Other (specify) \_\_\_\_\_

---

## **Biotechnology/Chemical Division**

*Scientific and Technical Information Center*

### **Search Results Feedback Form**



The results for your recent search request are attached. If you have any questions or comments about the scope or the results of the search, please contact the searcher whose name is stamped below.

Point of Contact:

Barb O'Bryen

Technical Info. Specialist

CM1 12C14 Tel: 308-4291

John Dantzman 308-4488

Jan Delaval 308-4498

Mary Hale 308-4258

Susan Hanley 305-4053

Edward Hart 305-9203

Barb O'Bryen 308-4291

Toby Port 308-3534

David Schreiber 308-4292

Beverly Shears 308-4994

Paula Sheppard 308-4499

Mona Smith 308-3278

Alex Wacławiw 308-4491

---

#### **Compliment or Complaint, contact:**

Stephanie Publicker

Information Branch Chief – STIC

Phone: 308-4740

Arti Shah

Division Chief – Biotech/Chem Division – STIC

Phone: 308-4259

---

=> fil reg; d stat que l8; fil capl; d que nos l9

FILE 'REGISTRY' ENTERED AT 15:59:09 ON 21 AUG 2000.  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 American Chemical Society (ACS)


STRUCTURE FILE UPDATES: 20 AUG 2000 HIGHEST RN 286833-04-3  
DICTIONARY FILE UPDATES: 20 AUG 2000 HIGHEST RN 286833-04-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

L6 STR



VAR G1=C/N  
VAR G2=2/3/4  
REP G3=(0-1) O  
VPA 20-8/9/10 U  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
MLEVEL IS CLASS AT 14 23  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE  
L8 172 SEA FILE=REGISTRY SSS FUL L6

100.0% PROCESSED 102627 ITERATIONS  
SEARCH TIME: 00.00.15

172 ANSWERS

FILE 'CAPLUS' ENTERED AT 15:59:10 ON 21 AUG 2000  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
Searched by Barb O'Bryen, STIC 308-4291

COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 21 Aug 2000 VOL 133 ISS 9  
FILE LAST UPDATED: 20 Aug 2000 (20000820/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

L6 STR  
L8 172 SEA FILE=REGISTRY SSS FUL L6  
L9 6 SEA FILE=CAPLUS ABB=ON L8

=> d ibib abs hitstr 19 1-6; fil cao; d que nos 110

L9 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2000 ACS  
ACCESSION NUMBER: 1999:282201 CAPLUS  
DOCUMENT NUMBER: 130:311793  
TITLE: Preparation of amides as antidiabetics  
INVENTOR(S): Maruyama, Tatsuya; Suzuki, Takayuki; Onda, Kenichi;  
Hayakawa, Masahiko; Moritomo, Hiroyuki; Kimizuka,  
Tetsuya; Matsui, Tetsuo  
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 45 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:



*Applicants*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920607	A1	19990429	WO 1998-JP4671	19981015
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9889288	A1	19990506	AU 1998-89288	19981013
AU 9894621	A1	19990510	AU 1998-94621	19981015
EP 1028111	A1	20000816	EP 1998-947894	19981015
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	Searched by Barb O'Bryen, STIC 308-4291			

CN 1218045	A	19990602	CN 1998-121375	19981016
NO 2000001983	A	20000414	NO 2000-1983	20000414
PRIORITY APPLN. INFO.:			JP 1997-285778	19971017
			WO 1998-JP4671	19981015

OTHER SOURCE(S): MARPAT 130:311793

GI



AB The title compds. I [ring B = an optionally substituted heteroaryl optionally fused with a benzene ring; X = a bond, lower alkylene or lower alkenylene (optionally substituted by hydroxy or lower alkyl), carbonyl, or NH (further details related to X are given); A = a lower alkylene or a group represented by (lower alkylene)-O; R1a and R1b = hydrogen or lower alkyl; R2 = hydrogen or halogeno; and Z = nitrogen or CH] are prepd. I are useful as diabetes remedies which not only function to accelerate the secretion of insulin and enhance insulin sensitivity but also have an anti-obesity action and an antihyperlipemic action based on their selective stimulative action on .beta.3 receptor. For example, imidazole deriv. II was prepd. Compds. of this invention significantly decreased blood sugar in mice.

IT 223672-09-1P 223672-10-4P 223672-11-5P  
 223672-12-6P 223672-13-7P 223672-14-8P  
 223672-15-9P 223672-16-0P 223672-17-1P  
 223672-18-2P 223672-19-3P 223672-20-6P  
 223672-21-7P 223672-22-8P 223672-23-9P  
 223672-24-0P 223672-25-1P 223672-26-2P  
 223672-27-3P 223672-29-5P 223672-30-8P  
 223672-31-9P 223672-32-0P 223672-34-2P  
 223672-36-4P 223672-38-6P 223672-40-0P  
 223672-42-2P 223672-44-4P 223672-46-6P  
 223672-47-7P 223672-48-8P 223672-49-9P  
 223672-50-2P 223672-51-3P 223672-52-4P  
 223672-53-5P 223672-55-7P 223672-58-0P  
 223672-60-4P 223672-63-7P 223672-65-9P  
 223672-66-0P 223672-67-1P 223672-68-2P  
 223672-69-3P 223672-70-6P 223672-71-7P  
 223672-72-8P 223672-73-9P 223672-74-0P  
 223672-75-1P 223672-76-2P 223672-77-3P  
 223672-78-4P 223672-79-5P 223672-80-8P

Searched by Barb O'Bryen, STIC 308-4291


223672-81-9P 223672-82-0P 223672-83-1P  
223672-84-2P 223672-85-3P 223672-86-4P  
223672-87-5P 223672-88-6P 223672-89-7P  
223672-90-0P 223672-91-1P 223672-92-2P  
223672-93-3P 223672-94-4P 223672-95-5P  
223672-96-6P 223672-97-7P 223672-98-8P  
223672-99-9P 223673-00-5P 223673-01-6P  
223673-02-7P 223673-03-8P 223673-04-9P  
223673-05-0P 223673-06-1P 223673-07-2P  
223673-08-3P 223673-09-4P 223673-10-7P  
223673-11-8P 223673-12-9P 223673-13-0P  
223673-14-1P 223673-15-2P 223673-16-3P  
223673-17-4P 223673-18-5P 223673-19-6P  
223673-20-9P 223673-21-0P 223673-22-1P  
223673-23-2P 223673-25-4P 223673-26-5P  
223673-27-6P 223673-28-7P 223673-29-8P  
223673-30-1P 223673-31-2P 223673-32-3P  
223673-33-4P 223673-58-3P 223673-59-4P  
223673-60-7P 223673-61-8P 223673-62-9P  
223673-63-0P 223673-64-1P 223673-65-2P  
223673-66-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of amides as antidiabetics)

RN 223672-09-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-10-4 CAPLUS

CN 8-Quinolinecarboxamide, N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-11-5 CAPLUS

CN 2-Propenamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-3-(2-pyridinyl)-, dihydrochloride, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.

● 2 HCl

RN 223672-12-6 CAPLUS

CN 2-Benzothiazoleacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-13-7 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291

CN Imidazo[2,1-b]thiazole-5-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-14-8 CAPLUS

CN 4-Thiazoleacetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-15-9 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● 2 HCl

RN 223672-16-0 CAPLUS  
CN 1H-Tetrazole-5-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-17-1 CAPLUS  
CN 1H-1,2,4-Triazole-3-acetamide, 2,5-dihydro-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-5-thioxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

Searched by Barb O'Bryen, STIC 308-4291

RN 223672-18-2 CAPLUS  
CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-19-3 CAPLUS  
CN 1,2,4-Thiadiazole-3-acetamide, 5-amino-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-20-6 CAPLUS  
CN Carbamic acid, [3-[2-[[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]amino]-2-oxoethyl]-1,2,4-thiadiazol-5-yl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-21-7 CAPLUS

CN 4-Thiazoleacetamide, 2-[(3-fluorophenyl)amino]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-22-8 CAPLUS

CN 2-Pyridineacetamide, 6-chloro-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-23-9 CAPLUS  
CN 2-Pyridineacetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-6-(phenylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-24-0 CAPLUS  
CN 1H-Imidazole-2-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-methyl-2-propenyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-25-1 CAPLUS  
CN 1H-Imidazole-4-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-26-2 CAPLUS

CN 1H-Imidazole-4-acetamide, 1-[(2-chlorophenyl)methyl]-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-27-3 CAPLUS

CN 1H-Imidazole-4-acetamide, 1-[(3-chlorophenyl)methyl]-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

Searched by Barb O'Bryen, STIC 308-4291

RN 223672-29-5 CAPLUS  
CN 1H-Imidazole-4-acetamide, 1-[(4-chlorophenyl)methyl]-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-30-8 CAPLUS  
CN 1H-Imidazole-2-acetamide, 1-[(4-fluorophenyl)methyl]-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-31-9 CAPLUS  
CN 1H-Imidazole-2-acetamide, 1-[(4-bromophenyl)methyl]-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-32-0 CAPLUS  
CN 1H-Imidazole-2-acetamide, N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[(4-iodophenyl)methyl]]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-34-2 CAPLUS  
CN 1H-Imidazole-2-acetamide, N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[[4-(trifluoromethyl)phenyl]methyl]]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-36-4 CAPLUS  
 CN 1H-Imidazole-2-acetamide, N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-naphthalenyl)-, dihydrochloride (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-38-6 CAPLUS  
 CN 1H-Imidazole-2-acetamide, 1-[(4-fluorophenyl)methyl]-N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-5-methyl-, dihydrochloride (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.






● 2 HCl

RN 223672-40-0 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-fluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-methyl-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-42-2 CAPLUS

CN 1H-Tetrazole-5-acetamide, 1-[(4-fluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-44-4 CAPLUS  
CN 1H-Tetrazole-5-acetamide, 1-[(3,4-dichlorophenyl)methyl]-N-[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-46-6 CAPLUS  
CN 2H-Tetrazole-5-acetamide, 2-[(4-fluorophenyl)methyl]-N-[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-47-7 CAPLUS

CN 1H-1,2,4-Triazole-3-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-48-8 CAPLUS

CN 1H-1,2,4-Triazole-3-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-5-[(phenylmethyl)thio]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

Searched by Barb O'Bryen, STIC 308-4291

RN 223672-49-9 CAPLUS  
CN 4-Thiazoleacetamide, 2-(acetylamino)-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-50-2 CAPLUS  
CN 4-Thiazoleacetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-2-[(methylsulfonyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-51-3 CAPLUS  
CN 4-Thiazoleacetamide, 2-[(aminoiminomethyl)amino]-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-52-4 CAPLUS  
CN 4-Thiazoleacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-2-(phenylamino)-, monohydrochloride (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-53-5 CAPLUS  
CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-[(4-nitrophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-55-7 CAPLUS  
CN 4-Thiazolecarboxamide, 2-amino-N-[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-58-0 CAPLUS  
CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-5-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-60-4 CAPLUS

CN 4-Thiazolepropanamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-63-7 CAPLUS

CN 4-Benzothiazolecarboxamide, 2-amino-4,5,6,7-tetrahydro-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

Searched by Barb O'Bryen, STIC 308-4291

RN 223672-65-9 CAPLUS  
CN Imidazo[2,1-b]thiazole-2-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223672-66-0 CAPLUS  
CN 1H-1,2,4-Triazole-3-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223672-67-1 CAPLUS  
CN 4-Thiazoleacetamide, 2,3-dihydro-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-3-(phenylmethyl)-2-thioxo-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 223672-68-2 CAPLUS

CN 8-Quinolinecarboxamide, 5,6,7,8-tetrahydro-N-[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-69-3 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-70-6 CAPLUS  
 CN 1H-Imidazole-2-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[[4-(1-methylethyl)phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-71-7 CAPLUS  
 CN 1H-Imidazole-2-acetamide, 1-([1,1'-biphenyl]-4-ylmethyl)-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-72-8 CAPLUS  
CN 1H-Imidazole-2-acetamide, 1-[(2-chlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 223672-73-9 CAPLUS  
CN 1H-Imidazole-2-acetamide, 1-[(3-chlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-74-0 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(3,4-dichlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 223672-75-1 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291

Absolute stereochemistry.




● 2 HCl

RN 223672-76-2 CAPLUS

CN 4-Thiazoleacetamide, 2-amino-.alpha.-hydroxy-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223672-77-3 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-methylpropyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-78-4 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2-fluorophenyl)methyl]-N-[4-[2-[[1-(4-isobutyl-1H-imidazol-2-yl)ethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-79-5 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(3-fluorophenyl)methyl]-N-[4-[2-[[1-(4-isobutyl-1H-imidazol-2-yl)ethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-80-8 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2,4-difluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223672-81-9 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2,6-difluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-82-0 CAPLUS  
 CN 1H-Imidazole-2-acetamide, 1-[(3,5-difluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 223672-83-1 CAPLUS  
 CN 1H-Imidazole-2-acetamide, 1-[(2,5-difluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291



Absolute stereochemistry.




● 2 HCl

RN 223672-84-2 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(3,4-difluorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 223672-85-3 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)  
Searched by Barb O'Bryen, STIC 308-4291

phenylethyl]amino]ethyl]phenyl]-1-[(2,3,6-trifluorophenyl)methyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-86-4 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[(2,4,5-trifluorophenyl)methyl]-,  
dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

● 2 HCl


Searched by Barb O'Bryen, STIC 308-4291

RN 223672-87-5 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[(3,4,5-trifluorophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 223672-88-6 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[(pentafluorophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 223672-89-7 CAPLUS  
CN 1H-Imidazole-2-acetamide, N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[(3-iodophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-90-0 CAPLUS  
CN 1H-Imidazole-2-acetamide, 1-[(2,6-dichlorophenyl)methyl]-N-[4-[2-[[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291

Absolute stereochemistry.




● HCl

RN 223672-91-1 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-cyanophenyl)methyl]-N-[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-92-2 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-quinolinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl

RN 223672-93-3 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2-chloro-6-fluorophenyl)methyl]-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223672-94-4 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2-chloro-4-fluorophenyl)methyl]-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223672-95-5 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(2,5-dichlorophenyl)methyl]-N-[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-96-6 CAPLUS

CN Benzoic acid, 4-[[2-[2-[[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]amino]-2-oxoethyl]-1H-imidazol-1-yl]methyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 223672-97-7 CAPLUS  
 CN 1H-Imidazole-2-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-[[4-(1-piperidinylcarbonyl)phenyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223672-98-8 CAPLUS  
 CN 1H-Pyrazole-1-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)  
 Searched by Barb O'Bryen, STIC 308-4291



Absolute stereochemistry.




● HCl

RN 223672-99-9 CAPLUS

CN 1H-1,2,4-Triazole-1-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223673-00-5 CAPLUS

CN 1H-Benzimidazole-1-acetamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

Searched by Barb O'Bryen, STIC 308-4291

RN 223673-01-6 CAPLUS  
CN 3-Pyridineacetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223673-02-7 CAPLUS  
CN 4-Pyridineacetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223673-03-8 CAPLUS  
CN 2-Pyridinepropanamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-04-9 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(2-phenylethyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 223673-05-0 CAPLUS

CN 1H-Benzimidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-06-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-07-2 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 223673-08-3 CAPLUS  
 CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223673-09-4 CAPLUS  
 CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223673-10-7 CAPLUS  
 CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-11-8 CAPLUS

CN 2-Pyridineacetamide, N-[4-[(2R)-2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]propyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-12-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[(2S)-2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]propyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-13-0 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[(2S)-2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]propyl]phenyl]-1-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223673-14-1 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-(2-fluorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 223673-15-2 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-(3-fluorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 223673-16-3 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-(4-fluorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 223673-17-4 CAPLUS  
 CN 2-Quinolineacetamide, N-[4-[2-[[2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223673-18-5 CAPLUS  
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 223673-19-6 CAPLUS  
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 223673-20-9 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-chlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-21-0 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223673-22-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[3-[[ (2R)-2-hydroxy-2-phenylethyl]amino]propyl]phenyl]-, monohydrochloride (9CI) (CA INDEX  
Searched by Barb O'Bryen, STIC 308-4291

Searched by Barb O'Bryen, STIC 308-4291

NAME)

Absolute stereochemistry.




● HCl

RN 223673-23-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-25-4 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]-2-methylpropyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 223673-26-5 CAPLUS

CN Urea, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-N'-2-pyridinyl-, dihydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291

Absolute stereochemistry.




● 2 HCl

RN 223673-27-6 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-28-7 CAPLUS

CN 1H-Tetrazole-5-acetamide, 1-[(3,4-dichlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 223673-29-8 CAPLUS  
CN 1H-1,2,4-Triazole-5-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(phenylmethyl)-, dihydrochloride (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 223673-30-1 CAPLUS  
CN 2-Pyridineacetamide, 6-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-31-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-32-3 CAPLUS

CN Pyrazineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-33-4 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291

CN 2-Pyrimidineacetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 223673-58-3 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-59-4 CAPLUS

CN 1H-Imidazole-2-acetamide, 1-[(4-chlorophenyl)methyl]-N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-60-7 CAPLUS

CN 1H-Tetrazole-5-acetamide, 1-[(3,4-dichlorophenyl)methyl]-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-61-8 CAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223673-62-9 CAPLUS

CN 1H-1,2,4-Triazole-5-acetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Searched by Barb O'Bryen, STIC 308-4291

Absolute stereochemistry.




RN 223673-63-0 CAPLUS  
CN 2-Pyridineacetamide, 6-amino-N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 223673-64-1 CAPLUS  
CN 2-Pyridineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-65-2 CAPLUS  
CN Pyrazineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 223673-66-3 CAPLUS

CN 2-Pyrimidineacetamide, N-[4-[2-[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 223673-45-8 223673-47-0 223673-48-1

223673-49-2 223673-50-5 223673-51-6

223673-52-7 223673-53-8 223673-56-1

223673-57-2


RL: RCT (Reactant)

(prepn. of amides as antidiabetics)

RN 223673-45-8 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl][2-[4-[(1H-imidazol-2-ylacetyl)amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223673-47-0 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl][2-[4-[(1H-1,2,4-triazol-3-ylacetyl)amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291


Absolute stereochemistry.



RN 223673-48-1 CAPLUS

CN Carbamic acid, [2-[4-[(2-amino-4-thiazolyl)carbonyl]amino]phenyl]ethyl] [(2R)-2-hydroxy-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-49-2 CAPLUS

CN Carbamic acid, [2-[4-[(2-amino-4-thiazolyl)oxoacetyl]amino]phenyl]ethyl] [(2R)-2-hydroxy-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223673-50-5 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl] [2-[4-[[[6-(phenylmethoxy)-2-(2-amino-4-thiazolyl)ethyl]amino]phenyl]ethyl] [(2R)-2-hydroxy-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Searched by Barb O'Brien, STIC 308-4291

pyridinyl]acetyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-51-6 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl] (phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-52-7 CAPLUS

CN 1H-Benzimidazole-2-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl] (phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-53-8 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl] (phenylmethyl)amino]ethyl]phenyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-56-1 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl][2-[4-[(2-pyridinylacetyl)amino]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-57-2 CAPLUS

CN Carbamic acid, [1,1-dimethyl-2-[4-[(2-pyridinylacetyl)amino]phenyl]ethyl][(2R)-2-hydroxy-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 223673-37-8P 223673-38-9P 223673-39-0P  
223673-41-4P 223673-44-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of amides as antidiabetics)

RN 223673-37-8 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl][2-[4-[(2-pyridinylcarbonyl)amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Searched by Barb O'Bryen, STIC 308-4291



RN 223673-38-9 CAPLUS

CN Carbamic acid, [(2R)-2-hydroxy-2-phenylethyl][2-[4-[(8-quinolinylcarbonyl)amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 223673-39-0 CAPLUS

CN Carbamic acid, [2-[4-[[[1-[(2-fluorophenyl)methyl]-1H-imidazol-2-yl]acetyl]amino]phenyl]ethyl][(2R)-2-hydroxy-2-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 223673-41-4 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291

CN 2-Pyridineacetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl] (phenylmethyl) amino] ethyl] phenyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 223673-44-7 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[ (2R)-2-hydroxy-2-phenylethyl] (phenylmethyl) amino] ethyl] phenyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

10

REFERENCE(S):

- (1) Merck & Co Inc; JP 07-10827 A 1995
  - (2) Merck & Co Inc; US 5553475 A 1995
  - (5) Merck & Co Inc; US 5541197 A 1997 CAPLUS
  - (7) Merck & Co Inc; WO 95/29159 A1 1997 CAPLUS
  - (10) Takeda Chem Ind Ltd; EP 643050 A1 1996 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1998:535771 CAPLUS

DOCUMENT NUMBER: 129:198012

TITLE: Preparation of phenethanol derivatives and their use as antidiabetic agents

INVENTOR(S): Maruyama, Tatsuya; Onta, Kenichi; Hayakawa, Akihiko; Matsui, Tetsuo

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1  
Searched by Barb O'Bryen, STIC 308-4291

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10218861	A2	19980818	JP 1997-21870	19970204

OTHER SOURCE(S): MARPAT 129:198012

GI For diagram(s), see printed CA Issue.


AB The derivs. I [ring B = II, III, IV; X, Y = O, S, NR6; R1 = H, lower alkyl; R2 = H, lower alkyl, NHSO2Me, NHCOR3; R3 = H, lower alkyl, mono- or di(lower alkylamino), aryl, aralkyl; R4, R5 = H, lower alkyl, amino; R6 = H, lower alkyl, aralkyl] or their salts as .beta.3-adrenoceptor agonists are prepd. Antidiabetic agents contg. I or thir salts as active ingredients are also claimed. I decreased blood glucose of obese and hyperglycemic kk mice with insulin resistance upon both oral and percutaneous administrations. I also increased insulin secretion in normal rats. Prepn. of some of I was given.

IT 211636-04-3P 211636-05-4P 211636-06-5P  
 211636-07-6P 211636-08-7P 211636-09-8P  
 211636-10-1P 211636-11-2P 211636-13-4P  
 211636-15-6P 211636-17-8P 211636-18-9P  
 211636-19-0P 211636-20-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of antidiabetic phenethanol derivs. as .beta.3-adrenoceptor agonists)

RN 211636-04-3 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-4-methyl-, monohydrochloride (9CI)  
 (CA INDEX NAME)



● HCl


RN 211636-05-4 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-5-methyl-, monohydrochloride (9CI)  
 (CA INDEX NAME)




● HCl

RN 211636-06-5 CAPLUS  
CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 211636-07-6 CAPLUS  
CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-4,6-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-08-7 CAPLUS  
CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 211636-09-8 CAPLUS  
CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291






● HCl

RN 211636-10-1 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(3-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-11-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(2-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-13-4 CAPLUS


CN 1H-Benzimidazole-2-acetamide, N-[4-[2-[[2-hydroxy-2-(2-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211636-12-3

CMF C25 H26 N4 O3

Searched by Barb O'Bryen, STIC 308-4291




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 211636-15-6 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]ethyl]phenyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211636-14-5

CMF C24 H27 N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 211636-17-8 CAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[[2-hydroxy-2-(2-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, hydrochloride trifluoroacetate (2:1:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211636-16-7


CMF C21 H24 N4 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 211636-18-9 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-hydroxy-3-  
[(methylsulfonyl)amino]phenyl]ethyl]methylamino]ethyl]phenyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 211636-19-0 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(formylamino)-4-hydroxyphenyl]-2-  
hydroxyethyl]methylamino]ethyl]phenyl]-, monohydrochloride (9CI) (CA  
INDEX NAME)




● HCl

RN 211636-20-3 CAPLUS  
 CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(acetylamino)-4-hydroxyphenyl]-2-hydroxyethyl]methylamino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 211635-78-8P 211635-79-9P 211635-80-2P  
 211635-81-3P 211635-86-8P 211635-87-9P  
 211635-88-0P 211635-89-1P 211635-92-6P  
 211635-93-7P 211635-94-8P 211635-95-9P  
 211635-96-0P 211635-97-1P 211636-00-9P  
 211636-03-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of antidiabetic phenethanol derivs. as .beta.3-adrenoceptor  
 agonists)  
 RN 211635-78-8 CAPLUS  
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-3-methyl-  
 (9CI) (CA INDEX NAME)



RN 211635-79-9 CAPLUS  
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-3-methyl-  
 Searched by Barb O'Bryen, STIC 308-4291

(phenylmethoxy)phenyl]ethyl] (phenylmethyl) amino]ethyl]phenyl]-4-methyl-  
(9CI) (CA INDEX NAME)




PAGE 1-B

—CH<sub>2</sub>—Ph

RN 211635-80-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl] (phenylmethyl) amino]ethyl]phenyl]-5-methyl-  
(9CI) (CA INDEX NAME)




PAGE 1-B

—CH<sub>2</sub>—Ph


RN 211635-81-3 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl] (phenylmethyl) amino]ethyl]phenyl]-6-methyl-  
(9CI) (CA INDEX NAME)




RN 211635-86-8 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl] (phenylmethyl) amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211635-87-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— CH<sub>2</sub>— Ph


RN 211635-88-0 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[3-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-89-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[2-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-92-6 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 211635-93-7 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[3-[(methanesulfonyl)amino]-4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-94-8 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[3-nitro-4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-95-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-amino-4-(phenylmethoxy)phenyl]-2-hydroxyethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-96-0 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(formylamino)-4-(phenylmethoxy)phenyl]-2-hydroxyethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-97-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(acetylamino)-4-(phenylmethoxy)phenyl]-2-hydroxyethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211636-00-9 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[[2-hydroxy-2-[2-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 211636-03-2 CAPLUS

CN Carbamic acid, [2-[4-[[2-amino-4-thiazolyl]acetyl]amino]phenyl]ethyl][2-hydroxy-2-(4-hydroxyphenyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1998:269995 CAPLUS

DOCUMENT NUMBER: 128:303693

TITLE: New Azole Antifungals. 3. Synthesis and Antifungal

Activity of 3-Substituted-4(3H)-quinazolinones

AUTHOR(S): Bartroli, Javier; Turmo, Enric; Alguero, Monica;


Boncompte, Eulalia; Vericat, Maria L.; Conte, Lourdes;

Ramis, Joaquim; Merlós, Manuel; Garcia-Rafanell,

Searched by Barb O'Bryen, STIC 308-4291



CORPORATE SOURCE: Julian; Forn, Javier  
Research Center, J. Uriach Cia. S.A., Barcelona,  
08026, Spain  
SOURCE: J. Med. Chem. (1998), 41(11), 1869-1882  
CODEN: JMCMAR; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



AB A series of azole antifungal agents featuring a quinazolinone nucleus have been subjected to studies of structure-activity relationships. In general, these compds. displayed higher in vitro activities against filamentous fungi and shorter half-lives than the structures described in our preceding paper. The most potent products in vitro carried a halogen (or an isostere) at the 7-position of the quinazolinone ring. Using a murine model of systemic candidosis, oral activity was found to be dependent on hydrophobicity, which, in turn, modulated the compd.'s half-life. The 7-Cl deriv., (1R,2R)-7-chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-((1H-1,2,4-triazol-1-yl)propyl)]quinazolin-4(3H)-one [I, UR-9825], was selected for further testing due to its high in vitro activity, low toxicity, good pharmacokinetic profile, and ease of obtention. Compd. I is the (1R,2R) isomer of four possible stereoisomers. The other three isomers were also prepd. and tested. The enantiomer (1S,2S) and the (1R,2S) epimer were inactive, whereas the (1S,2R) epimer retained some activity. In vitro, I was superior to fluconazole, itraconazole, SCH-42427, and TAK-187 and roughly similar to voriconazole and ER-30346. In vivo, I was only moderately active in a mouse model of systemic candidosis when administration was limited to the first day. This was attributed to its short half-life in that species ( $t_{1/2} = 1$  h po). Protection levels comparable to or higher than those of fluconazole, however, were obsd. in systemic candidosis models in rat and rabbit, where the half-life of the compd. was found to be 6 and 9 h, resp. Finally, I showed excellent protection levels in an immunocompromised rat model of disseminated aspergillosis. The compd. showed low toxicity signs when administered to rats at 250 mg/kg qd or at 100 mg/kg bid during 28 days.

IT 206350-06-3P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones)

RN 206350-06-3 CAPLUS

CN Benzamide, 4-chloro-N-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-((1H-1,2,4-triazol-1-yl)propyl)-2-(formylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Searched by Barb O'Bryen, STIC 308-4291



L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1992:426440 CAPLUS

DOCUMENT NUMBER: 117:26440

TITLE: Triazole antifungals. IV. Synthesis and antifungal activities of 3-acylamino-2-aryl-2-butanol derivatives

AUTHOR(S): Konosu, Toshiyuki; Tajima, Yawara; Takeda, Noriko; Miyaoka, Takeo; Kasahara, Mayumi; Yasuda, Hiroshi; Oida, Sadao

CORPORATE SOURCE: Med. Chem. Res. Lab., Sankyo Co., Ltd., Tokyo, 140, Japan


SOURCE: Chem. Pharm. Bull. (1991), 39(10), 2581-9

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB New triazoles, e.g., I (R = 4-Cl, 2,4-Cl<sub>2</sub>, 2,4-F<sub>2</sub>; R<sub>1</sub> = H, Me; R<sub>2</sub> = H, CMe<sub>3</sub>, Ph, substituted Ph, 2-furyl, 2-thienyl) were designed and synthesized as potential inhibitors of the fungal cytochrome P 450 14.alpha.-demethylase. In testing for antifungal activity against a mouse systemic *Candida albicans* infection, (2R,3R)-3-acylamino-2-aryl-2-butanol derivs. exhibited remarkably high efficacy after oral or parenteral administration. The structure-activity relationships of these amido alcs. were evaluated.

IT 126916-61-8P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. and antifungal activity of)

RN 126916-61-8 CAPLUS

CN Benzamide, 4-(acetylamino)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-, (R\*,R\*)- (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291

Relative stereochemistry.



IT 138990-07-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 138990-07-5 CAPLUS


CN Benzamide, 4-(acetylamino)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-, (R\*,R\*)-, ethanedioate (1:1) (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 126916-61-8

CMF C21 H21 F2 N5 O3


Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



L9 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1990:631379 CAPLUS

DOCUMENT NUMBER: 113:231379

Searched by Barb O'Bryen, STIC 308-4291

TITLE: Preparation and formulation of (halophenyl)-1H-1,2,4-triazol-1-ylalkanols as medical and agrochemical fungicides

INVENTOR(S): Oida, Sadao; Tajima, Yawara; Konosu, Toshiyuki; Iwata, Masayuki; Takeda, Noriko; Miyaoka, Takeo; Takeshiba, Hideo; Nakanishi, Toshiro

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 160 pp.  
CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 332387	A1	19890913	EP 1989-302244	19890306
EP 332387	B1	19931124		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8901051	A	19890905	DK 1989-1051	19890303
FI 8901021	A	19890905	FI 1989-1021	19890303
FI 97382	B	19960830		
FI 97382	C	19961210		
NO 8900926	A	19890905	NO 1989-926	19890303
NO 171272	B	19921109		
NO 171272	C	19930217		
JP 02191262	A2	19900727	JP 1989-51336	19890303
HU 53889	A2	19901228	HU 1989-1034	19890303
CN 1036759	A	19891101	CN 1989-101072	19890304
CN 1029962	B	19951011		
AU 8931051	A1	19890907	AU 1989-31051	19890306
AU 622639	B2	19920416		
ZA 8901678	A	19901128	ZA 1989-1678	19890306
AT 97662	E	19931215	AT 1989-302244	19890306
ES 2061975	T3	19941216	ES 1989-302244	19890306
PRIORITY APPLN. INFO.:			JP 1988-51312	19880304
			JP 1988-68681	19880323
			JP 1988-250158	19881004
			JP 1988-261211	19881017
			EP 1989-302244	19890306

OTHER SOURCE(S): MARPAT 113:231379  
GI



AB Title compds. I (Ar = (un)substituted Ph; R<sub>1</sub> = H, C1-6 alkyl, etc.; R<sub>2</sub> = C1-6 alkyl, halo-C1-6-alkyl, (un)substituted Ph, naphthyl, (un)substituted 5-6-membered heterocyclyl; R<sub>3</sub> = H, substituted amino; X = C1-6 alkylene, C2-6 aliph. having 1 or 2 C-C double bonds, C2-6 aliph. having 1 or 2 C-C triple bonds, C3-6 cycloalkylene, etc.; Y = NR<sub>5</sub>CO, NR<sub>5</sub>COCH:CH, O<sub>2</sub>C, O<sub>2</sub>CCH:CH, SCO, SCOCH:CH, R<sub>5</sub> = H, C1-4 alkyl; m, n = 0, 1; YR<sub>2</sub> = N<sub>3</sub>, (un)substituted phthalimido. (un)substituted 1'-oxo-2,3-dihydro-2-indolyl)

Searched by Barb O'Bryen, STIC 308-4291

and acid addn. salts thereof, are prepd. I are useful as medical and agrochem. fungicides. When used as agrochem. fungicide's, I may be blended with other fungicides and insecticides for a broader fungicidal spectrum and synergistic effect. 4-ClC<sub>6</sub>H<sub>4</sub>COCl was added to (2R,3R)-3-amino-2-(2,4-dichlorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (prepn. given) to give (2R,3R)-I (Ar = 2,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>; R<sub>1</sub> = Me; R<sub>3</sub> = H; X<sub>m</sub> = O; YR<sub>2</sub> = 4-ClC<sub>6</sub>H<sub>4</sub>CONH) and converted to the oxalate salt (II). In rice seedlings inoculated with *Rhizoctonia solani*, II at 100 ppm (30 mL/3 pots), gave complete control. Mice inoculated with *Candida albicans* and administered orally II 20 mg/kg, showed 100% survival rate.


IT 126916-61-8P 126918-10-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. of, as fungicide)

RN 126916-61-8 CAPLUS

CN Benzamide, 4-(acetylamino)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-, (R\*,R\*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 126918-10-3 CAPLUS

CN Benzamide, 4-(acetylamino)-N-[2-(2,4-dichlorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-, (R\*,R\*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L9 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2000 ACS


ACCESSION NUMBER: 1990:98544 CAPLUS

DOCUMENT NUMBER: 112:98544

TITLE: Preparation and formulation of 5-hydroxy-8-[1-hydroxy-2-(2-methyl-2-propylamine)ethyl]-2H-1,4-benzoxazin-3-(4H)-ones and analogs containing a quaternary ammonium group as broncholytics  
Searched by Barb O'Bryen, STIC 308-4291

INVENTOR(S): Schromm, Kurt; Mentrup, Anton; Renth, Ernst Otto;  
 Muacevic, Gojko; Traunecker, Werner  
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Fed. Rep.  
 Ger.  
 SOURCE: Ger. Offen., 30 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3743265	A1	19890629	DE 1987-3743265	19871219
EP 321864	A2	19890628	EP 1988-121011	19881215
EP 321864	A3	19901227		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8809387	A	19900829	ZA 1988-9387	19881215
DK 8807007	A	19890620	DK 1988-7007	19881216
FI 8805811	A	19890620	FI 1988-5811	19881216
NO 8805598	A	19890620	NO 1988-5598	19881216
AU 8827022	A1	19890622	AU 1988-27022	19881216
AU 618302	B2	19911219		
DD 280099	A5	19900627	DD 1988-323312	19881216
SU 1628854	A3	19910215	SU 1988-4613149	19881216
JP 02000239	A2	19900105	JP 1988-320315	19881219
HU 53866	A2	19901228	HU 1988-6491	19881219
HU 207283	B	19930329		
PL 160685	B1	19930430	PL 1988-276549	19881219
US 5223614	A	19930629	US 1990-603585	19901025
PRIORITY APPLN. INFO.:			DE 1987-3743265	19871219
			US 1988-286442	19881219
OTHER SOURCE(S):	MARPAT 112:98544			
GI				



AB QCH(OH)CHR<sub>4</sub>NHCR<sub>5</sub>R<sub>6</sub>(CH<sub>2</sub>)<sub>n</sub>R (Q = Ph group of a broncholytically effective compd., e.g., Q1(R<sub>1</sub> = H); R = quaternary ammonium group contg.-alkoxy, -heterocyclyl, -arylalkoxy, etc.; R<sub>4</sub> = H, Me, Et; R<sub>5</sub>, R<sub>6</sub> = H, Me; n = 1-5) were prepd. Thus, Q1COCH(OH)OEt (R<sub>1</sub> = Bz) was condensed with 4-(Me<sub>2</sub>N)C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CM<sub>2</sub>NH<sub>2</sub> and the product treated with NaBH<sub>4</sub> to give Q1CH(OH)CH<sub>2</sub>NHCM<sub>2</sub>CH<sub>2</sub>1C<sub>6</sub>H<sub>4</sub>NMe<sub>2</sub>-4 (R<sub>1</sub> = Bz) which was condensed with BrCH<sub>2</sub>CO<sub>2</sub>Et to give, after hydrolysi and hydrogenolysis, Q1CH(OH)CH<sub>2</sub>NHCM<sub>2</sub>CH<sub>2</sub>2C<sub>6</sub>H<sub>4</sub>R<sub>2</sub>-4 (I) (R<sub>1</sub> = H; R<sub>2</sub> = N+Me<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>-) (II). I [R<sub>1</sub> = H; R<sub>2</sub> = OCH<sub>2</sub>CH<sub>2</sub>N+Me<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>-) gave 50% protection against acetylcholine-induced spasm in guinea pigs after inhalation of a 0.004% aq. soln. An aerosol was prepd. contg. II 0.1, sorbitan trioleate 0.5, and CFC13 and CF<sub>2</sub>Cl<sub>2</sub> (2:3) 99.4 wt. %.


IT 124955-21-1P 124955-32-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 Searched by Barb O'Bryen, STIC 308-4291

(prepn. of, as broncholytic)


RN 124955-21-1 CAPLUS

CN Pyridinium, 1-[2-[[4-[2-[[2-(3,4-dihydro-5-hydroxy-3-oxo-2H-1,4-benzoxazin-8-yl)-2-hydroxyethyl]amino]-2-methylpropyl]phenyl]amino]-2-oxoethyl]-, chloride, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


● Cl<sup>-</sup>

● HCl

RN 124955-32-4 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291

CN Pyridinium, 1-[[[4-[2-[[2-hydroxy-2-[4-hydroxy-3-  
[(methoxysulfonyl)amino]phenyl]ethyl]amino]-2-  
methylpropyl]phenyl]amino]carbonyl]oxy]methyl]-, chloride,  
monohydrochloride (9CI) (CA INDEX NAME)



● Cl<sup>-</sup>

● HCl

FILE 'CAOLD' ENTERED AT 16:00:52 ON 21 AUG 2000  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L6 STR  
L8 172 SEA FILE=REGISTRY SSS FUL L6  
L10 0 SEA FILE=CAOLD ABB=ON L8 \*



=> fil beil; d stat que l15

FILE 'BEILSTEIN' ENTERED AT 16:01:20 ON 21 AUG 2000

COPYRIGHT (c) 2000 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE LAST UPDATED: 6 MAR 2000

FILE COVERS 1779 TO 2000.


\*\*\* CAS REGISTRY NUMBERS FOR 4,356,237 SUBSTANCES AVAILABLE \*\*\*

\*\*\* FILE CONTAINS 7,688,486 SUBSTANCES \*\*\*

\*\*\*\*\*  
\* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. \*  
\* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE \*  
\* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE \*  
\* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. \*  
\* FOR PRICE INFORMATION SEE HELP COST \*  
\*\*\*\*\*

L6

STR



Hy 23

VAR G1=C/N

VAR G2=2/3/4

REP G3=(0-1) O

VPA 20-8/9/10 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 14 23

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

L15 2 SEA FILE=BEILSTEIN SSS FUL L6

100.0% PROCESSED 32705 ITERATIONS


2 ANSWERS

SEARCH TIME: 00.00.34

=> d ide pre 115 1-2; fil hom

L15 ANSWER 1 OF 2 COPYRIGHT 2000 BEILSTEIN CDS MDL

Beilstein Reg. No. (BRN): 7956379 Beilstein  
Molecular Formula (MF): C20 H18 Cl F2 N5 O3  
Autonom Name (AUN): 4-chloro-N-<2-(2,4-difluoro-phenyl)-2-hydroxy-1-methyl-3-<1,2,4>triazol-1-yl-propyl>-2-formylamino-benzamide  
Beilstein Reference (SO): 6-26  
General Comments (NTE): Stereo compound  
Formula Weight (FW): 449.84  
Lawson Number (LN): 29971; 16524; 16039; 1145



Atom/Bond Notes:

1. CIP Descriptor: R

Preparation:

PRE

Start: BRN=7983052 (1R,2R)-7-chloro-3-<2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl>quinazolin-4(3H)-one

Reag: 0.1N aq. NaOH

Time: 3 hour(s)

Yield: 25.00 %

Solv: tetrahydrofuran

Ambient Temperature

Reference(s):


1. Bartroli, Javier; Turmo, Enric; Alugero, Monica; Boncompte, Eulalia; Vericat, Maria L.; et al., J.Med.Chem., 41 <1998> 11, 1869-1882, LA: EN, CODEN: JMCMAR

*Same as CAPLUS answer #3*

L15 ANSWER 2 OF 2 COPYRIGHT 2000 BEILSTEIN CDS MDL

Beilstein Reg. No. (BRN): 4892790 Beilstein  
Molecular Formula (MF): C21 H21 F2 N5 O3  
Autonom Name (AUN): 4-acetylamino-N-<2-(2,4-difluoro-phenyl)-2-hydroxy-1-methyl-3-<1,2,4>triazol-1-yl-propyl>-benzamide  
Beilstein Reference (SO): 6-26  
General Comments (NTE): Stereo compound: racemate  
Searched by Barb O'Bryen, STIC 308-4291

CAS Reg. No. (RN): 126916-61-8  
Beilstein Pref. RN (BPR): 126916-61-8  
Formula Weight (FW): 429.43  
Lawson Number (LN): 29971; 16524; 16038; 1155



## Atom/Bond Notes:

1. CIP Descriptor: R

## Fragment Notes:

Additionally represents mirror image

## Preparation:

PRE

Start: BRN=4297530 (2R\*,3R\*)-3-Amino-2-(2,4-difluoropropyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol, BRN=513757 p-acetylamino benzoyl chloride

Reag: pyridine

Yield: 51.00 %

Temp: 0.0 Cel

## Reference(s):


1. Konosu, Toshiyuki; Tajima, Yawara; Takeda, Noriko; Miyaoka, Takeo; Kasahara, Mayumi; et al., Chem.Pharm.Bull., 39 <1991> 10, 2581-2589, LA: EN, CODEN: CPBTAL

*Same as CAPLUS answer #4*

FILE 'HOME' ENTERED AT 16:01:34 ON 21 AUG 2000

Best Available Copy

L9 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2000 ACS  
 ACCESSION NUMBER: 1992:426440 CAPLUS  
 DOCUMENT NUMBER: 117:26440  
 TITLE: Triazole antifungals. IV. Synthesis and antifungal activities of 3-acylamino-2-aryl-2-butanol derivatives  
 AUTHOR(S): Konosu, Toshiyuki; Tajima, Yawara; Takeda, Noriko; Miyaoka, Takeo; Kasahara, Mayumi; Yasuda, Hiroshi; Oida, Sadao  
 CORPORATE SOURCE: Med. Chem. Res. Lab., Sankyo Co., Ltd., Tokyo, 140, Japan  
 SOURCE: Chem. Pharm. Bull. (1991), 39(10), 2581-9  
 DOCUMENT TYPE: CODEN: CPBTAL; ISSN: 0009-2363  
 LANGUAGE: Journal  
 GI English




AB New triazoles, e.g., I (R = 4-Cl, 2,4-Cl<sub>2</sub>, 2,4-F<sub>2</sub>; R<sub>1</sub> = H, Me; R<sub>2</sub> = H, CMe<sub>3</sub>, Ph, substituted Ph, 2-furyl, 2-thienyl) were designed and synthesized as potential inhibitors of the fungal cytochrome P 450 14.alpha.-demethylase. In testing for antifungal activity against a mouse systemic *Candida albicans* infection, (2R,3R)-3-acylamino-2-aryl-2-butanol derivs. exhibited remarkably high efficacy after oral or parenteral administration. The structure-activity relationships of these amido alcs. were evaluated.

IT 126916-61-8P  
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and antifungal activity of)

RN 126916-61-8 CAPLUS  
 CN Benzamide, 4-(acetylamino)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-. (R\*.R\*)- (9CI) (CA INDEX NAME)  
 Searched by Barb O'Bryen, STIC 308-4291

Relative stereochemistry.



IT 138990-07-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 138990-07-5 CAPLUS


CN Benzamide, 4-(acetylamino)-N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-, (R\*,R\*)-, ethanedioate (1:1) (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 126916-61-8

CMF C21 H21 F2 N5 O3


Relative stereochemistry.



CM 2

CRN 144-62-7

CMF C2 H2 O4



ACCESSION NUMBER: 1990:98544 CAPLUS

DOCUMENT NUMBER: 112:98544

TITLE: Preparation and formulation of 5-hydroxy-8-[1-hydroxy-2-(2-methyl-2-propylamine)ethyl]-2H-1,4-benzoxazin-3-(4H)-ones and analogs containing a quaternary ammonium group as broncholytics

INVENTOR(S): Schromm, Kurt; Mentrup, Anton; Renth, Ernst Otto; Muacevic, Gojko; Traunecker, Werner

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Fed. Rep. Ger.

SOURCE: Ger. Offen., 30 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3743265	A1	19890629	DE 1987-3743265	19871219
EP 321864	A2	19890628	EP 1988-121011	19881215
EP 321864	A3	19901227		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8809387	A	19900829	ZA 1988-9387	19881215
DK 8807007	A	19890620	DK 1988-7007	19881216
FI 8805811	A	19890620	FI 1988-5811	19881216
NO 8805598	A	19890620	NO 1988-5598	19881216
AU 8827022	A1	19890622	AU 1988-27022	19881216
AU 618302	B2	19911219		
DD 280099	A5	19900627	DD 1988-323312	19881216
SU 1628854	A3	19910215	SU 1988-4613149	19881216
JP 02000239	A2	19900105	JP 1988-320315	19881219
HU 53866	A2	19901228	HU 1988-6491	19881219
HU 207283	B	19930329		
PL 160685	B1	19930430	PL 1988-276549	19881219
US 5223614	A	19930629	US 1990-603585	19901025

## PRIORITY APPLN. INFO.:

DE 1987-3743265 19871219  
US 1988-286442 19881219

OTHER SOURCE(S): MARPAT 112:98544

GI



AB QCH(OH)CHR<sub>4</sub>NHCR<sub>5</sub>R<sub>6</sub>(CH<sub>2</sub>)<sub>n</sub>R (Q = Ph group of a broncholytically effective compd., e.g., Q1(R<sub>1</sub> = H); R = quaternary ammonium group contg.-alkoxy, -heterocyclyl, -arylalkoxy, etc.; R<sub>4</sub> = H, Me, Et; R<sub>5</sub>, R<sub>6</sub> = H, Me; n = 1-5) were prepd. Thus, Q1COCH(OH)OEt (R<sub>1</sub> = Bz) was condensed with 4-(Me<sub>2</sub>N)C<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>CMe<sub>2</sub>NH<sub>2</sub> and the product treated with NaBH<sub>4</sub> to give Q1CH(OH)CH<sub>2</sub>NH<sub>2</sub>CMe<sub>2</sub>CH<sub>2</sub>1C<sub>6</sub>H<sub>4</sub>NMe<sub>2</sub>-4 (R<sub>1</sub> = Bz) which was condensed with BrCH<sub>2</sub>CO<sub>2</sub>Et to give, after hydrolysis and hydrogenolysis, Q1CH(OH)CH<sub>2</sub>NH<sub>2</sub>CMe<sub>2</sub>CH<sub>2</sub>2C<sub>6</sub>H<sub>4</sub>R<sub>2</sub>-4 (I) (R<sub>1</sub> = H; R<sub>2</sub> = N+Me<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>-) (II). I [R<sub>1</sub> = H; R<sub>2</sub> = OCH<sub>2</sub>CH<sub>2</sub>N+Me<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>SO<sub>2</sub>-] gave 50% protection against acetylcholine-induced spasm in guinea pigs after inhalation of a 0.004% aq. soln. An aerosol was prepd. contg. II 0.1, sorbitan trioleate 0.5, and CFCl<sub>3</sub> and CF<sub>2</sub>Cl<sub>2</sub> (2:3) 99.4 wt. %.

IT 124955-21-1P 124955-32-4P

RL: SPN (Synthetic preparation); PREP (Preparation)


Searched by Barb O'Bryen, STIC 308-4291

(prepn. of, as broncholytic)


RN 124955-21-1 CAPLUS

CN Pyridinium, 1-[2-[[4-[2-[[2-(3,4-dihydro-5-hydroxy-3-oxo-2H-1,4-benzoxazin-8-yl)-2-hydroxyethyl]amino]-2-methylpropyl]phenyl]amino]-2-oxoethyl]-, chloride, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


● Cl<sup>-</sup>

● HCl

RN 124955-32-4 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291

CN Pyridinium, 1-[[[[[4-[2-[[2-hydroxy-2-[4-hydroxy-3-  
[(methoxysulfonyl)amino]phenyl]ethyl]amino]-2-  
methylpropyl]phenyl]amino]carbonyl]oxy]methyl]-, chloride,  
monohydrochloride (9CI) (CA INDEX NAME)



● Cl<sup>-</sup>

● HCl



ACCESSION NUMBER: 1998:535771 CAPLUS

DOCUMENT NUMBER: 129:198012

TITLE: Preparation of phenethanol derivatives and their use  
as antidiabetic agents

INVENTOR(S): Maruyama, Tatsuya; Onta, Kenichi; Hayakawa, Akihiko;  
Matsui, Tetsuo

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1  
Searched by Barb O'Bryen, STIC 308-4291

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10218861	A2	19980818	JP 1997-21870	19970204

OTHER SOURCE(S): MARPAT 129:198012

GI For diagram(s), see printed CA Issue.


AB The derivs. I [ring B = II, III, IV; X, Y = O, S, NR6; R1 = H, lower alkyl; R2 = H, lower alkyl, NHSO2Me, NHCOR3; R3 = H, lower alkyl, mono- or di(lower alkylamino), aryl, aralkyl; R4, R5 = H, lower alkyl, amino; R6 = H, lower alkyl, aralkyl] or their salts as .beta.3-adrenoceptor agonists are prepd. Antidiabetic agents contg. I or thir salts as active ingredients are also claimed. I decreased blood glucose of obese and hyperglycemic kk mice with insulin resistance upon both oral and percutaneous administrations. I also increased insulin secretion in normal rats. Prepn. of some of I was given.

IT 211636-04-3P 211636-05-4P 211636-06-5P  
 211636-07-6P 211636-08-7P 211636-09-8P  
 211636-10-1P 211636-11-2P 211636-13-4P  
 211636-15-6P 211636-17-8P 211636-18-9P  
 211636-19-0P 211636-20-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of antidiabetic phenethanol derivs. as .beta.3-adrenoceptor agonists)

RN 211636-04-3 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-4-methyl-, monohydrochloride (9CI)  
 (CA INDEX NAME)



● HCl

RN 211636-05-4 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-5-methyl-, monohydrochloride (9CI)  
 (CA INDEX NAME)



● HCl

RN 211636-06-5 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-07-6 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-4,6-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-08-7 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 211636-09-8 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-6-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291




● HCl

RN 211636-10-1 CAPLUS  
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(3-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-11-2 CAPLUS  
 CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(2-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 211636-13-4 CAPLUS  
 CN 1H-Benzimidazole-2-acetamide, N-[4-[2-[[2-hydroxy-2-(2-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211636-12-3  
 CMF C25 H26 N4 O3

Searched by Barb O'Bryen, STIC 308-4291




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 211636-15-6 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]ethyl]phenyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211636-14-5

CMF C24 H27 N3 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 211636-17-8 CAPLUS

CN 4-Thiazoleacetamide, 2-amino-N-[4-[2-[[2-hydroxy-2-(2-hydroxyphenyl)ethyl]amino]ethyl]phenyl]-, hydrochloride trifluoroacetate (2:1:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 211636-16-7


CMF C21 H24 N4 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 211636-18-9 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-hydroxy-3-  
[(methylsulfonyl)amino]phenyl]ethyl]methylamino]ethyl]phenyl]-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 211636-19-0 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(formylamino)-4-hydroxyphenyl]-2-  
hydroxyethyl]methylamino]ethyl]phenyl]-, monohydrochloride (9CI) (CA  
INDEX NAME)



● HCl

RN 211636-20-3 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(acetamino)-4-hydroxyphenyl]-2-hydroxyethyl]methylamino]ethyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 211635-78-8P 211635-79-9P 211635-80-2P  
 211635-81-3P 211635-86-8P 211635-87-9P  
 211635-88-0P 211635-89-1P 211635-92-6P  
 211635-93-7P 211635-94-8P 211635-95-9P  
 211635-96-0P 211635-97-1P 211636-00-9P  
 211636-03-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of antidiabetic phenethanol derivs. as .beta.3-adrenoceptor agonists)

RN 211635-78-8 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 211635-79-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-3-methyl- Searched by Barb O'Bryen, STIC 308-4291

(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino]ethyl]phenyl]-4-methyl-  
(9CI) (CA INDEX NAME)




PAGE 1-B

—CH<sub>2</sub>—Ph

RN 211635-80-2 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino]ethyl]phenyl]-5-methyl-  
(9CI) (CA INDEX NAME)




PAGE 1-B

—CH<sub>2</sub>—Ph

RN 211635-81-3 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino]ethyl]phenyl]-6-methyl-  
(9CI) (CA INDEX NAME)



RN 211635-86-8 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[4-(phenylmethoxy)phenyl]ethyl] (phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)





RN 211635-87-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

—CH<sub>2</sub>—Ph


RN 211635-88-0 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(3-phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211635-89-1 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(2-phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 211635-92-6 CAPLUS


CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-(4-phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291




RN 211635-93-7 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[[3-[(methanesulfonyl)amino]-4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-94-8 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-hydroxy-2-[[3-nitro-4-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-95-9 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-amino-4-(phenylmethoxy)phenyl]-2-hydroxyethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-96-0 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(formylamino)-4-(phenylmethoxy)phenyl]-2-hydroxyethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211635-97-1 CAPLUS

CN 2-Pyridineacetamide, N-[4-[2-[[2-[3-(acetylamino)-4-(phenylmethoxy)phenyl]-2-hydroxyethyl](phenylmethyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 211636-00-9 CAPLUS

CN 1H-Imidazole-2-acetamide, N-[4-[2-[[2-hydroxy-2-[2-(phenylmethoxy)phenyl]ethyl](phenylmethyl)amino]ethyl]phenyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 211636-03-2 CAPLUS

CN Carbamic acid, [2-[4-[(2-amino-4-thiazolyl)acetyl]amino]phenyl]ethyl][2-hydroxy-2-(4-hydroxyphenyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L9 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1998:269995 CAPLUS

DOCUMENT NUMBER: 128:303693

TITLE: New Azole Antifungals. 3. Synthesis and Antifungal  
Activity of 3-Substituted-4(3H)-quinazolinones

AUTHOR(S): Bartroli, Javier; Turmo, Enric; Alguero, Monica;  
Boncompte, Eulalia; Vericat, Maria L.; Conte, Lourdes;  
Ramis, Joaquim; Merlos, Manuel; Garcia-Rafanell,  
Searched by Barb O'Bryen, STIC 308-4291



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/529,096 04/07/00 MARUYAMA

T 07385.0007

HM12/1027  
FINNEGAN HENDERSON FARABOW  
GARRETT & DUNNER  
1300 I STREET NW  
WASHINGTON DC 20005-3315

EXAMINER

PATEL, S

ART UNIT

PAPER NUMBER

1624

4

DATE MAILED:

10/27/00

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**

# Office Action Summary

Application No.  
09/529,096

Applicant

Tatsuya Maruyama et al.

Examiner

Sudhaker Patel

Group Art Unit

1624



☐ Responsive to communication(s) filed on \_\_\_\_\_

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 35 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 1 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claim

☒ Claim(s) 1-8 is/are pending in the application

Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration

☐ Claim(s) \_\_\_\_\_ is/are allowed.

☐ Claim(s) \_\_\_\_\_ is/are rejected.

☐ Claim(s) \_\_\_\_\_ is/are objected to.

☒ Claims 1-8 are subject to restriction or election requirement.

## Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some\* ☒ None of the CERTIFIED copies of the priority documents have been

☐ received.

☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

☐ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

— SEE OFFICE ACTION ON THE FOLLOWING PAGES —

Art Unit: 1624

## DETAILED ACTION

### *Election/Restrictions*

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

**Group I**, claim(s) 1-3,6-8, drawn to compounds, composition, and method of use for **Formula I** where in  $Z = N$ ;  $B = 6$ -membered rings containing at least 1 N and one other heteroatom (O,N,S) e.g. 1,4-, 1,3- diazine, piperazine, morpholine, thiomorpholine etc.

**Group II**, claim(s) 1-3,6-8, drawn to compounds, composition, and method of use for **Formula I** where in  $Z = N$ ;  $B = 6$ -membered rings containing 1 N & 5 carbons, e.g. pyridine, piperidine, quinoline etc..

**Group III**, claim(s)1-3,6-8, drawn to compounds, composition, and method of use for **Formula I** where in  $Z = N$ ;  $B = 5$ -membered rings containing 1N and +0 to 3 heteroatoms (O,S,N) e.g. diazoles, triazoles, tetrazoles, Thiadiazoles, Thiazole etc..

**Group IV**, claim(s)1-1-4,5,6,7-8, drawn to compounds, composition, and method of use for Formula (I) wherein  $Z = CH$  If this group is elected, further restriction(s) will be required..

**Group V**, claim(s)1-8, drawn to compounds not included in above Groups I-IV.

Art Unit: 1624

In addition to election of one of the above groups, applicants are also required to elect a single species for the group.

2. The inventions listed as **Groups I-V** do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: They have different structures.

3. A telephone call was made to Mr. Hill on 10/24/00 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicants are advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventor ship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventor ship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker Patel whose telephone number is (703) 308 4709. The examiner can normally be reached on Monday thru' Friday from 8:30 AM to 5:00 PM. If attempts to reach

Art Unit: 1624


the examiner by the phone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached at (703) 308 4716.

A facsimile center has been established for Group 1600. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machine are (703) 308-4556 or (703) 305-3592.

Any inquiry of general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308 1235.

sp 

October 25, 2000

  
**Mukund J. Shah**

**Supervisory Patent Examiner**

**Art Unit 1624**